Brian O Mahony/X
Jul 21, 2025, 13:10
What’s Slowing Down Gene Therapy Uptake in Hemophilia? Brian O’Mahony Explains the Real-World Barriers
Brian O’Mahony, CEO of Irish Haemophilia Society,former President of WFH and EHC, highlights several key challenges that are currently limiting the widespread adoption of gene therapy in hemophilia in his recently shared post on X:
“Uncertainty about outcomes and side effects,
Complex reimbursement systems,
Availability of other excellent therapies,
Lack of center preparedness and resources.”
Despite the promise of a functional cure, real-world barriers continue to delay broader implementation.
Want to understand the future of gene therapy and how to overcome systemic obstacles?
Find the latest updates and expert commentary — only on Hemostasis Today, your trusted source for frontline academic insights in hematology and hemostasis.
-
Jun 13, 2026, 20:28Tarun Tyagi: Translational Insights into Severe Immune Thrombocytopenia
-
Jun 13, 2026, 18:25Miguel Gómez Álvarez: Reviewing Inflammation, Transplantation, and Gene Therapy in Hemoglobinopathies
-
Jun 13, 2026, 18:24Ana Pedrero Gil: Why Factor XIII Deficiency Is Often Overlooked During Acute Bleeding
-
Jun 13, 2026, 18:23Tobias Degsell: Building Stronger Bridges Across Disciplines, Countries, and Perspectives at EHA 2026
-
Jun 13, 2026, 18:22Haemoglobinopathies, Innovation, Patient Experience, and Equitable Access at EHA 2026 – TIF
-
Jun 13, 2026, 18:21Thomas Stauch: Discussing the Future of ITP Research and Patient Care
-
Jun 13, 2026, 17:11Kim De Keersmaecker: Advancing Hematology Through Shared Expertise at EHA 2026
-
Jun 13, 2026, 17:03Nour Al-Mozain: The Evolving Role of Apheresis Across Clinical Practice
-
Jun 13, 2026, 16:45Sarah Hendry: A Big Day for Gene Therapy Research at EHA 2026